DermTech Passes State of New York Laboratory Inspection with Zero Deficiencies
LA JOLLA, Calif.--(BUSINESS WIRE)--Nov 13, 2018--DermTech, Inc., the global leader in non-invasive molecular dermatology, passes State of New York, Department of Public Health inspection with zero deficiencies.
“We are proud to be part of the New York CLEP accreditation program and to support New York’s melanoma skin cancer testing needs,” said Darryl Garrison, DermTech’s Vice President of Operations. “Clinical labs receiving New York lab approval go through a detailed New York inspection as well as individual assay approval in order to receive this highly sought-after New York accreditation.”
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181113006120/en/
CONTACT: DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: DermTech, Inc.
Copyright Business Wire 2018.
PUB: 11/13/2018 02:55 PM/DISC: 11/13/2018 02:55 PM